男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

New vaccine protects the previously infected

By WANG XIAOYU | China Daily | Updated: 2021-09-24 09:59
Share
Share - WeChat
Taxi driver Zheng Ruiwen (front) puts on a protective gown before setting off to transport COVID-19 nucleic acid samples in Putian, Fujian province, on Sept 23, 2021. [Photo by ZHANG BIN/CHINA NEWS SERVICE]

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

The vaccine candidate is 92 percent effective against the Gamma variant first identified in Brazil, and 59 percent against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organization that funded the clinical trial.

The vaccine's overall efficacy rate against all strains in the study was 67 percent. It was also 100 percent effective in preventing severe cases and hospitalizations, and nearly 84 percent effective in preventing moderate to severe cases, the statement said.

The vaccine is the "first COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally", it said.

The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.

Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.

More than 30,000 adults-some of them elderly-in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo.

Like the inactivated vaccines widely deployed in China, the experimental vaccine can be stored at regular refrigerated temperatures of 2 to 8 C, making its transportation and distribution easier.

The company said it plans to submit applications for conditional market approval to global regulatory authorities in the fourth quarter of the year and is aiming for a potential market launch by the end of the year.

Clover Biopharmaceuticals is also a supplier to COVAX, an international initiative that distributes vaccines to low- and middle-income countries.

The company signed an advance purchase agreement with Gavi, one of the co-leaders of COVAX, in late June to provide 414 million doses of its vaccine to the initiative by next year.

However, the product has to first gain emergency use authorization from the World Health Organization, which is anticipated in the fourth quarter of this year, according to Gavi.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 特克斯县| 新巴尔虎右旗| 随州市| 崇礼县| 仙游县| 十堰市| 苏州市| 灵宝市| 普格县| 剑阁县| 娱乐| 台中市| 香河县| 灵山县| 桂林市| 信阳市| 庆城县| 东安县| 二连浩特市| 旬阳县| 库车县| 毕节市| 洛南县| 迁西县| 长寿区| 如东县| 昔阳县| 嘉祥县| 加查县| 积石山| 额尔古纳市| 南投市| 故城县| 陇西县| 荔波县| 开远市| 镇原县| 富宁县| 布尔津县| 抚顺市| 兖州市|